ClinicalTrials.gg
RecruitingNCT07949006HORUSUpdated Nov 19, 2026

Evalutation of Ocular Symptoms in Asymptomatic Carotid Artery Stenosis

An observational study in Carotid Stenosis and Ocular Blood Flow, sponsored by University of Bologna. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 150 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Bologna · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 150 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Carotid Stenosis with a site in Italy — 3 open to participants now, 5 under way, none of them phase 3. Carotid Stenosis · Italy.

Planned enrollment
3rd of 11
300 · median 200
Started
2027
the only one that year
Observational
11 of 22
3 open now
Registered
22nd of 22
by date
Lead sponsor
2 of 22
University of Bologna

Among the 22 studies in Carotid Stenosis with a site in Italy, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2027, is one of 11 observational ones, and was the 22nd registered.

Carotid Stenosis

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

Browse Carotid Stenosis studies →

Open to participants now

3 of the 22 studies in Carotid Stenosis with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 150 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Carotid Stenosis with a site in Italy, or all of them as a file.
02

Study summary

The management of atherosclerotic carotid disease, according to current guidelines, is primarily based on the quantification of the degree of carotid stenosis, together with the assessment of its hemodynamic significance and the presence of neurological symptoms, such as transient ischemic attack (TIA) or stroke. However, these parameters may not fully reflect the hemodynamic impact of carotid lesions on peripheral vascular territories, particularly the ocular circulation.

The eye represents the only vascular territory that can be directly visualized in vivo, providing a unique "window" into the microcirculation. Retinal and choroidal abnormalities resulting from chronic hypoperfusion may reflect the degree of hemodynamic impairment associated with carotid disease and provide additional information beyond the anatomical characteristics of the stenosis identified by vascular imaging alone.

From a vascular surgery perspective, ophthalmological assessment and fundus examination could allow a more accurate phenotypic characterization of patients with carotid disease, identifying individuals in whom carotid stenosis has already resulted in end-organ microvascular consequences despite the absence of major neurological manifestations. In the era of personalized medicine, such a multidisciplinary approach could move beyond a purely morphological assessment of carotid plaque by incorporating functional and clinical parameters that may potentially contribute to therapeutic decision-making.

The results of the present study may therefore help define the role of fundus examination, combined with a more comprehensive assessment of ocular symptoms, as a complementary tool in the evaluation of patients with carotid stenosis. This approach may facilitate a more accurate identification of patients at higher risk of disease progression and cerebrovascular ischemic events, while potentially improving the selection of candidates for carotid revascularization procedures

03

Conditions studied

  • Carotid Stenosis
  • Ocular Blood Flow

Browse trials for

04

Who can participate

Ages eligible
18 Years to 150 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with asymptomatic carotid artery stenosis and ocular alterations

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asymptomatic carotid artery stenosis
  • Ocular alterations

Exclusion criteria

Exclusion Criteria:

  • Symptomatic carotid artery stenosis
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Patients

    Patients with asymptomatic carotid artery stenosis and ocular symptoms

06

What researchers measure

Primary outcomes

  1. Correlation between carotid stenosis and ocular symptoms

    Any ocular alteration correlated to carotid stenosis

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jul 2037, 126 months later.

Of 79 non-industry observational studies under Carotid Stenosis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 104. This study's planned 126 months is above that.

Counting every sponsor, half of 87 studies reached it within 50 months; a quarter within 30 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jul 31, 2037
CompletionEst.
Jul 31, 2037
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949006
Responsible party
Marcello Lodato (MD, University of Bologna) — Principal investigator
First posted
Nov 19, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jul 31, 2037 (estimated)
Completion
Jul 31, 2037 (estimated)
Last update
Nov 19, 2026

Study contacts

Marcello Lodato, MD
Contact
marcello.lodato7@gmail.com
+390512143288

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion